Aerska, which uses brain shuttle technology to deliver RNAi therapeutics to the brain, announced the close of a $39 million Series A financing round, bringing its total funding to $60 million. EQT ...

DUBLIN and LONDON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announced the close of a $39 ...

Trontinemab is the current frontrunner among Alzheimer’s disease drug candidates that use a “brain shuttle” to reach their intended target, but a growing pack of other shuttle contenders are already ...

Alzheimer’s disease can be treated with antibodies that clear away plaques of amyloid protein, but these medicines require frequent dosing and they introduce serious safety risks. Korsana Biosciences ...

The blood–brain barrier (BBB) is a protective filter that lines the brain's blood vessels and is notoriously hard to penetrate, making the treatment of brain disorders very difficult. Strategies ...

Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...

Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an ...

Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery using direct-to-vivo measurement, announced a major research collaboration and license agreement with Roche to develop ...

Newswise — Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the ...

The highly selective border lining the brain’s vasculature is the Achilles’ heel of any large therapeutic molecule aiming for targets in the brain, anti-Aβ antibodies included. Not only do fewer than ...